Upfront ICIs May Enhance Second-Line Responses in NSCLC
Second-line ramucirumab and docetaxel after use of immune checkpoint inhibitors may improve some outcomes for patients with NSCLC. The study was published as a preprint and has not yet been peer reviewed.
Source: medscape.com